Back to Search
Start Over
Real-world evidence of obinutuzumab and venetoclax in previously treated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.
- Source :
-
Leukemia & lymphoma [Leuk Lymphoma] 2024 May; Vol. 65 (5), pp. 653-659. Date of Electronic Publication: 2024 Jan 31. - Publication Year :
- 2024
-
Abstract
- Venetoclax-obinutuzumab (Ven-O) is frequently administered off-label in relapsed/refractory (r/r) CLL/SLL where venetoclax-rituximab is the approved regimen. We conducted this retrospective, real-world study to evaluate Ven-O in r/r CLL/SLL. Between 7/2019 and 6/2022, 40 patients with r/r CLL/SLL on Ven-O were included. The median age was 72, 28.2% had TP53 mutation and/or 17p deletion, median number of prior therapies was 1 (range, 1-6), and 55% had prior BTK inhibitor exposure. The overall response rate was 90% (complete response [CR] or CR with incomplete marrow recovery in 27.5% and partial response in 62.5%) of patients, and the 2-year progression-free survival was 81.2% (95% CI, 69.5-94.8). Therapy was well tolerated. No laboratory or clinical TLS occurred with venetoclax (Howard criteria). One (3%) patient experienced laboratory TLS with obinutuzumab initiation. In summary, this retrospective cohort study demonstrated that Ven-O achieves frequent, durable responses and can be safely administered in r/r CLL/SLL.
- Subjects :
- Humans
Aged
Female
Male
Middle Aged
Retrospective Studies
Aged, 80 and over
Treatment Outcome
Adult
Leukemia, Lymphocytic, Chronic, B-Cell drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell mortality
Leukemia, Lymphocytic, Chronic, B-Cell genetics
Leukemia, Lymphocytic, Chronic, B-Cell diagnosis
Leukemia, Lymphocytic, Chronic, B-Cell pathology
Sulfonamides administration & dosage
Sulfonamides therapeutic use
Sulfonamides adverse effects
Bridged Bicyclo Compounds, Heterocyclic therapeutic use
Bridged Bicyclo Compounds, Heterocyclic administration & dosage
Bridged Bicyclo Compounds, Heterocyclic adverse effects
Antibodies, Monoclonal, Humanized administration & dosage
Antibodies, Monoclonal, Humanized therapeutic use
Antibodies, Monoclonal, Humanized adverse effects
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Antineoplastic Combined Chemotherapy Protocols adverse effects
Subjects
Details
- Language :
- English
- ISSN :
- 1029-2403
- Volume :
- 65
- Issue :
- 5
- Database :
- MEDLINE
- Journal :
- Leukemia & lymphoma
- Publication Type :
- Academic Journal
- Accession number :
- 38293753
- Full Text :
- https://doi.org/10.1080/10428194.2024.2310144